<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43443">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01774825</url>
  </required_header>
  <id_info>
    <org_study_id>INQ/028111</org_study_id>
    <nct_id>NCT01774825</nct_id>
  </id_info>
  <brief_title>IQP-CL-101 in IBS Management</brief_title>
  <official_title>Double-blind, Randomized, Placebo-controlled, Bicentric Clinical Investigation to Evaluate the Safety and Efficacy of IQP-CL-101 in the Symptomatic Improvement of Irritable Bowel Syndrome (IBS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InQpharm Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InQpharm Group</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      After 2 weeks of run-in period, subjects are randomized to either IQP-CL-101 or a matching
      placebo. Over 8 weeks, the subjects are monitored for improvements in IBS symptoms
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>IBS-SSS (Severity Symptom Score)</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The questionnaire is to be completed by the subject</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IBS-GIS (Global Improvement Score)</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The questionnaire is to be completed by the subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IBS-QOL (Quality of Life)</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The questionnaire is to be completed by the subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain and discomfort diary</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The diary is to be completed by the subject on a daily basis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessment by investigator</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The investigator rates the efficacy of the investigational product using a 4-point Likert scale (poor, moderate, good, very good)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessment by subject</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The subject rates the efficacy of the investigational product using a 4-point Likert scale (poor, moderate, good, very good)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Full blood count</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>After sampling, venous blood samples will be transported on same day in cooler boxes to a central laboratory for analysis of hemoglobin, hematocrit, erythrocytes, thrombocytes, and leucocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical chemistry</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Venous blood samples are obtained at screening and the end of the study (8 weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal calprotectin</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The samples will be later tested by an enzyme immunoassay (ELISA) specific for calprotectin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Sitting blood pressure and heart rate will be measured using standard devices</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessment by subject</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The subject rates the safety of the IP using a 4-point Likert scale (poor, moderate, good, very good)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessment by investigator</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The investigator rates the safety of the IP using a 4-point Likert scale (poor, moderate, good, very good)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>At all visits, subjects will be asked if any AE has occurred; such events will be recorded in the source documents and case report forms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>IQP-CL-101</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 softgels twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 softgels twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>IQP-CL-101</intervention_name>
    <description>2 softgels twice a day</description>
    <arm_group_label>IQP-CL-101</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 softgels twice a day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fulfils Rome-III criteria for IBS diagnosis

          -  Females' agreement to use appropriate birth control methods during the active study
             period for females of childbearing potential

          -  Subject declares in writing his/her consent to participate, understands requirements
             of the study and is willing to comply

        Exclusion Criteria:

          -  Known sensitivity to any of the ingredients of IQP-CL-101

          -  Clinically relevant abnormalities in colonoscopy within the last 2 years prior to
             randomization

          -  Other causes of IBS symptoms such as inflammatory bowel disease (IBD), microscopic
             colitis, celiac disease, history of abdominal obstruction, cholecystitis,
             pancreatitis, ileus, or any gastrointestinal bleeding

          -  Use of medications that could influence GI functions (e.g. antibiotics, laxatives,
             opioids, glucocorticoids, anticholinergics, or anti-diarrheals) within 1 month prior
             to randomization

          -  Clinically relevant excursions of safety parameters

          -  Any other conditions deemed relevant by the investigator(s)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Grube, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Private practice</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Grube</name>
      <address>
        <city>Berlin</city>
        <zip>10709</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 13, 2014</lastchanged_date>
  <firstreceived_date>January 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Irritable bowel syndrome</keyword>
  <keyword>IBS</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
